Two muramyl dipeptides, N-acetylmuramyl-L-alanyl-D-isoglutamine and its adjuvant-inactive isomer Nacetylmuramyl-D-alanyl-D-isoglutamine, were examined for their ability to protect mice carrying the CBA/N immune deficiency gene (xid) against lethal bacterial challenge. Prophylactic treatment with N-acetylmuramyl-L-alanyl-d-isoglutamine gave significant protection against Streptococcus pneumoniae, Salmonella typhimurium, and Salmonella enteritidis infection. N-Acetylmuramyl-D-alanyl-D-isoglutamine was unable to confer protection. Incorporation of the lipophilic glycerol dipalmitate derivatives of the two muramyl dipeptides within liposomal carriers resulted in a significant enhancement of anti-infectious activity, both with respect to number of survivors and length of survival. Liposomal muramyl dipeptides were 10-to 15-fold more potent than free muramyl dipeptide; enhanced potency was most evident with N-acetylmuramyl-D-alanyl-D-isoglutamine. Prophylactic treatment with liposomes containing the lipophilic muramyl dipeptides resulted in enhanced clearance of bacteria from the blood (>3-fold increase in rate) when compared with that of hydrosoluble N-acetylmuramyl-L-alanyl-D-isoglutamine, indicating a correlation between reticuloendothelial stimulation and anti-infectious activity.
N-Acetylmuramyl-L-alanyl-D-isoglutamine (MDP) is the minimum structure possessing immunoadjuvant activity which can be isolated from and replace Freund complete adjuvant (3, 5) . In addition to its ability to stimulate a number of macrophage functions such as monokine production (13, 23) , collagenase and prostaglandin secretion (33) , and inhibition of tumor cell growth (27) , MDP is capable of stimulating resistance to bacterial infections in rodents (2, 4, 8, 11, 15, 18) .
CBA/N mice possess a sex-linked defect in the ability to produce antibodies against thymus-independent type 2 antigens (31) . This defect is expressed as an increased susceptibility toward a number of microbial agents, notably malaria (12) and Salmonella typhimurium (20, 21) . These mice therefore provide a model to investigate the effect of enhancing nonspecific resistance in the absence of concomitant humoral immunity. Multiple (but not single) injections of MDP and the lipophilic derivative MDP-L18 have been shown to be effective in protecting CBA/N mice against a lethal challenge of virulent Salmonella enteritidis (22) The rapid excretion of MDP after parenteral administration (1, 29) may, however, result in a suboptimal activation of the protective mechanisms involved in nonspecific defenses. The ability of liposomal carriers to target encapsulated muramyl dipeptides to the reticuloendothelial system provides a strategy for optimizing the effect of muramyl dipeptides by changing their pharmacokinetic profile (10) . Such approaches have been effective in inhibiting tumor growth via macrophage activation in rodents (19 Liposome preparation. Distearoylphosphatidylcholine (DSPC) and dimyristoylphosphatidylglycerol (DMPG) were purchased from Avanti Polar Lipids, Inc., Birmingham, Ala. Liposomes were prepared as previously described (30) . Briefly, the phospholipids were dissolved in anhydrous chloroform and placed in round-bottom flasks in the molar ratio of 10:1 (DSPC-DMPG). After rotary evaporation at 45°C, liposomes were prepared by adding phosphatebufferedsaline to the flask, followed by vigorous shaking at 56°C. MDP-GDP and MDP(D-D)-GDP were incorporated into the liposomes by adding appropriate quantities of their chloroform solutions to the admixed DSPC-DMPG before rotary evaporation (27) . All Clearance of S. enteritidis from blood after muramyl dipeptide treatment. Mice were treated intravenously with muramyl dipeptides, empty liposomes, or liposomes containing muramyl dipeptide-GDP derivatives. After 24 h, 2 x 105 S. enteritidis bacteria were injected intravenously in a volume of 200 ,ul. Blood was collected from the retro-orbital plexus in heparinized capillary tubes 30 and 90 min after bacterial challenge and was serially diluted, and the bacterial count was determined 24 h after plating on nutrient agar.
Statistical analysis. The effect of treatment on the survival of the mice after bacterial challenge was determined by chi-square analysis with the Yates' correction for continuity (Streptococcus pneumoniae) (35) or by the Fisher exact probability test (6) . Relative potency determinations were carried out with dose-response data (32) .
RESULTS
Susceptibility of CDF1 versus DCF1 hybrids. Initial experiments were carried out to determine the susceptibility of CDF1 mice to Streptococcus pneumoniae. S. typhimurium, or S. enteritidis challenge. (8) .
The ability of MDP to induce nonspecific protection in mice occurs in the presence of rapid excretory mechanismrs (1, 25) and often requires high or multiple doses to achieve significant activity (4, 8, 9, 15, 18, 22, 24) . Liposomal encapsulation provides an efficient method of directing biologically active compounds to the reticuloendothelial system via phagocytic mechanisms: liposomal incorporation of MDP has been shown to be more efficacious than free MDP in inducing macrophage tumoricidal activity both in vitro and in vivo (19) . However, the liposomal retention characteristics of MDP are not sufficient to provide a stable formulation (28) . Lipophilic muramyl dipeptide derivatives, based on coupling to molecules such as GDP or cholesterol, have recently been described and possess a number of advantages over MDP in terms of efficiency of liposome incorporation and subsequent retention (28, 29) . The lipophilic detivatives MDP-GDP (28) and MDP(D-D)-GDP (N. C. Phillips, L. Chedid, J. M. Bernard, and P. Lefrancier, submitted for publication) have been shown to be several orders of magnitude more potent than free MDP in inducing macrophage-mediated tumoricidal activity either in vitro or in vivo. This report demonstrates that such liposomal formulations are also several orders of magnitude more efficacious than free muramyl dipeptides in protecting CBA/N mice against a number of pathogenic organisms. This enhanced activity appears to correlate with the ability of the liposomal muramyl dipeptides to stimulate bacterial clearance from the blood. The slight activity observed with control liposomes in this assay may be a reflection of the ability of phosphatidylcholine to stimulate carbon clearance (14) or resistance to infection in the mouse (7) . Such activity profiles, coupled with the known propensity of the reticuloendothelial system for liposomes, strongly implicate the fixed macrophages of the liver and spleen as the effector cells. Further support for the role of tissue-fixed macrophages comes from the observation that the antimicrobial activity of several immunomodulators is independent of the level of circulating monocytes or natural killer cells (17) .
CBA/N mice possess a genetic defect, xid, which is X-linked and confers a B-lymphocyte functional defect which results in enhanced susceptibility to Salmonella spp. This defect has been shown to correlate with a delayed and diminished antibody response against the bacteria (20, 21 ). An MDP analog, MDP-Lys(L18), has been shown to increase the resistance of immunodeficient CBA/N mice to S. enteritidis only after several consecutive treatments: single doses of MDP-Lys(L18) or of MDP given before bacterial challenge are ineffective in conferring protection (22) . The data presented in this study show that free MDP or liposomes containing a lipophilic MDP derivative, MDP-GDP, were able to confer significant protection after a single intravenous injection. MDP(D-D), the adjuvant-inactive (3) , nonpyrogenic (26) isomer of MDP, was unable to confer protection. The ability of liposomes containing MDP(D-D)-GDP to confer protection was an unexpected observation. The supposition that liposomes are able to efficiently target muramyl dipeptides to the effector organs was validated by the observations that the doses required for protection were significantly less than those of MDP (2 to 10 ,ug versus 100 ,ug, respectively).
The inability of muramyl dipeptide treatment to fully protect CBA/N mice against bacterial challenge may be a reflection of their impaired immunological response. The optimal time for muramyl dipeptide treatment in this model appears to be 1 to 3 days before bacterial challenge. Treat 
